Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZeeGab M
- Development stage
- Unknown
- Lead developer
- Precia Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ZeeGab M is a branded generic fixed-dose combination oral medication developed and marketed by Precia Pharma for the management of neuropathic pain. It contains two active ingredients: **pregabalin** (75 mg) and **methylcobalamin** (1500 mcg). Pregabalin is a gabapentinoid that acts as a ligand for the alpha-2 delta subunit of voltage-gated calcium channels, thereby modulating the release of excitatory neurotransmitters and reducing pain signaling. Methylcobalamin, a neuroactive form of vitamin B12, serves as a neuroprotective agent that promotes myelin sheath regeneration and supports the rejuvenation of damaged nerve cells. The drug is typically formulated as a sustained-release tablet and is indicated for conditions such as diabetic peripheral neuropathy, sciatica, and post-herpetic neuralgia.
- Brand names
- ZeeGab M
- Other names
- pregabalin + methylcobalaminpregabalin + mecobalamin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on ZeeGab M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZeeGab M.